By Stephen Nakrosis

Biotechnology company Moderna Inc. on Friday said it filed with the European Medicines Agency to request its Spikevax Covid-19 vaccine be authorized for children aged six months to under six years old.

Moderna said similar requests are underway with international regulatory authorities, based on a two-dose primary series of mRNA-1273, the research name used for Spikevax.

The company said its filing follows a Feb. 24 decision by the EMA's Committee for Medicinal Products for Human Use "to adopt a positive opinion recommending marketing authorization for Moderna's Covid-19 vaccine to include children six years of age and older."

According to Moderna, positive interim results from a Phase 2/3 study showed a "robust neutralizing antibody response in the six months to under six years of age group after a two-dose primary series of mRNA-1273, along with a favorable safety profile."

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

April 29, 2022 12:08 ET (16:08 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Moderna.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Moderna.